January 16, 2025
FDA Rejects Atara’s Ebvallo Due to Manufacturing Issues, Not Efficacy or Safety Concerns
Atara Therapeutics, Ebvallo, FDA rejection, manufacturing issues, post-transplant lymphoproliferative disease (PTLD), Epstein-Barr virus (EBV), T-cell immunotherapy, Pierre Fabre Laboratories.
Charles River Laboratories Forecasts Revenue Decline in 2025 Amid CDMO Challenges
Charles River Laboratories, CRL, 2025 revenue outlook, CDMO business challenges, biopharma spending constraints, pharmaceutical industry trends
Denmark’s AI and Biotech Advancements: No Direct Information on New Manufacturing Learning Center
Denmark, AI research center, biotech acquisitions, vocational education, manufacturing learning center
DEA Unveils Special Registration Framework for Telehealth Prescribing of Controlled Substances
DEA Special Registration, Telehealth Prescribing, Controlled Substances, Telemedicine Flexibilities, Ryan Haight Act, Telemedicine Regulations
FDA Approves Lilly’s Omvoh for Crohn’s Disease, Expanding Treatment Options
Omvoh, FDA approval, Crohn’s disease, inflammatory bowel disease, mirikizumab-mrkz, Eli Lilly
NVIDIA’s AI Innovations: Pioneering the Future of Artificial Intelligence
NVIDIA AI Innovations, Generative AI, Accelerated Computing, Robotics, AI in Healthcare, AI Foundation Models
Hinge Bio Secures $30 Million Series A’ Financing for Next-Generation Therapies via GEM-DIMER Platform
Hinge Bio, immune reset, GEM-DIMER platform, Series A’ financing, autoimmune diseases, HB2198, Systemic Lupus Erythematosus
OS Therapies Seeks Expedited FDA Approval Following Successful Mid-Stage Osteosarcoma Trial
OS Therapies, FDA approval, osteosarcoma, OST-HER2, mid-stage trial, expedited approval